Safety

Astagraf XL (tacrolimus extended-release capsules)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

December 2015

Summary View

DRUG INTERACTIONS

  • schisandra sphenanthera extracts

 

February 2014

Summary View

5 WARNINGS AND PRECAUTIONS

5.14 Use with CYP3A4 Inhibitors and Inducers
5.15 QT Prolongation …added section
5.18 Gastrointestinal Perforation …added section

6 ADVERSE REACTIONS

  • Added bullet point…Gastrointestinal Perforation [see Warnings and Precautions (5.18)]

7 DRUG INTERACTIONS

  • Dose adjustments may be needed along with frequent monitoring of tacrolimus whole blood trough concentrations when ASTAGRAF XL is administered with CYP3A inhibitors or inducers. In addition, patients should be monitored for adverse reactions including changes in renal function and QT prolongation [see Warnings and Precautions (5.9) and (5.15)]. 

Page Last Updated: 01/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English